Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma

Cancer Science

Volumn 104, Issue 5, 2013, Pages 563-572

  Takagi, Daisuke ^a,b   Tatsumi, Yasutoshi ^a   Yokochi, Tomoki ^a   Takatori, Atsushi ^a   Ohira, Miki ^a   Kamijo, Takehiko ^a   Kondo, Satoshi ^b   Fujii, Yoshitaka ^b   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANAPLASTIC LYMPHOMA KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN SRC HOMOLOGY 2 DOMAIN CONTAINING F; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CELL GROWTH; CELL MOTILITY; CONTROLLED STUDY; DOWNSTREAM PROCESSING; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NEUROBLASTOMA; PHOSPHORYLATION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84876406488     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12115     Document Type: Article

References (48)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
2. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005; 17: 7-13.
3. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-4.
4. Shiota M, Nakamura S, Ichinohasama R et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954-60.
5. Fujimoto J, Shiota M, Iwahara T et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 1996; 93: 4181-6.
6. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59: 2776-80.
7. Jazii FR, Najafi Z, Malekzadeh R et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006; 12: 7104-12.
8. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
9. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-203.
10. Iwahara T, Fujimoto J, Wen D et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439-49.
11. Morris SW, Naeve C, Mathew P et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175-88.
12. Vernersson E, Khoo NK, Henriksson ML, Roos G, Palmer RH, Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns 2006; 6: 448-61.
13. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008; 416: 153-9.
14. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-4.
15. George RE, Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-8.
16. Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-70.
17. Mosse YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-5.
18. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010; 29: 1566-79.
19. De Brouwer S, De Preter K, Kumps C et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010; 16: 4353-62.
20. Heukamp LC, Thor T, Schramm A et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 2012; 4: 141ra91.
21. Berry T, Luther W, Bhatnagar N et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012; 22: 117-30.
22. Lindholm CK, Frantz JD, Shoelson SE, Welsh M. Shf, a Shb-like adapter protein, is involved in PDGF-alpha-receptor regulation of apoptosis. Biochem Biophys Res Commun 2000; 278: 537-43.
23. Welsh M, Mares J, Karlsson T, Lavergne C, Breant B, Claesson-Welsh L. Shb is a ubiquitously expressed Src homology 2 protein. Oncogene 1994; 9: 19-27.
24. Oda T, Kujovich J, Reis M, Newman B, Druker BJ. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase. Oncogene 1997; 15: 1255-62.
25. Ohira M, Morohashi A, Inuzuka H et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003; 22: 5525-36.
26. Ohira M, Morohashi A, Nakamura Y et al. Neuroblastoma oligo-capping cDNA project: toward the understanding of the genesis and biology of neuroblastoma. Cancer Lett 2003; 2: 63-8.
27. Furuya T, Kamijo T, Ozaki T, Kusafuka T, Nakagawara A. Functional implication of the Shf in Neuroblastoma. Nichidai Igaku Zasshi 2006; 65: 367-75.
28. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77.
29. Kaneko M, Nishihira H, Mugishima H et al. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study group of Japan for treatment of Advanced Neuroblastoma, Tokyo, Japan. Med Pediatr Oncol 1998; 31: 1-7.
30. Machida T, Fujita T, Ooo ML et al. Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas. Oncogene 2006; 25: 1931-42.
31. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169: 107-14.
32. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54.
33. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
34. Zamo A, Chiarle R, Piva R et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-47.
35. Wan W, Albom MS, Lu L et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006; 107: 1617-23.
36. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005; 167: 213-22.
37. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-61.
38. Armstrong F, Duplantier MM, Trempat P et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004; 23: 6071-82.
39. Dupuis-Coronas S, Lagarrigue F, Ramel D et al. The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness. J Biol Chem 2011; 286: 32105-14.
40. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-56.
41. Hooshmand-Rad R, Lu L, Heldin CH, Claesson-Welsh L, Welsh M. Platelet-derived growth factor-mediated signaling through the Shb adaptor protein: effects on cytoskeletal organization. Exp Cell Res 2000; 257: 245-54.
42. Miyake I, Hakomori Y, Shinohara A et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002; 21: 5823-34.
43. Van der Geer P, Wiley S, Lai VK et al. A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides. Curr Biol 1995; 5: 404-12.
44. Pelicci G, Dente L, De Giuseppe A et al. A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Oncogene 1996; 13: 633-41.
45. Tamir I, Cambier JC. Antigen receptor signaling: integration of protein tyrosine kinase functions. Oncogene 1998; 11: 1353-64.
46. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998; 8: 49-54.
47. Miyake I, Hakomori Y, Misu Y et al. Domain-specific function of ShcC docking protein in neuroblastoma cells. Oncogene 2005; 24: 3206-15.
48. Bresler SC, Wood AC, Haglund EA et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011; 3: 108ra14.